Warfarin sodium or aspirin therapy to prevent stroke in nonrheumatic atrial fibrillation. Answered and unanswered questions.
作者信息
Stratton J R
出版信息
West J Med. 1995 Aug;163(2):177-9.
Abstract
摘要
相似文献
1
2
Antithrombotic therapy in atrial fibrillation.心房颤动的抗栓治疗
Can Fam Physician. 1996 Jul;42:1341-5.
3
Warfarin versus aspirin in the elderly in primary prophylaxis for atrial fibrillation.华法林与阿司匹林用于老年患者心房颤动一级预防的比较
Age Ageing. 2007 Mar;36(2):117-9. doi: 10.1093/ageing/afl181. Epub 2007 Jan 25.
4
Prevention of cardioembolic stroke with anticoagulant therapy.抗凝治疗预防心源性栓塞性卒中
Ann Neurol. 1996 Mar;39(3):281-2. doi: 10.1002/ana.410390302.
5
Warfarin, aspirin, and atrial fibrillation.华法林、阿司匹林与心房颤动。
Harv Heart Lett. 1998 Aug;8(12):4-6.
6
Primary prevention of stroke.
N Engl J Med. 1996 Apr 25;334(17):1138; author reply 1139. doi: 10.1056/NEJM199604253341716.
7
[Atrial fibrillation and apoplexy--risks and prevention].[心房颤动与中风——风险与预防]
Nord Med. 1996 Jun;111(6):171-5.
8
Atrial fibrillation and stroke. Three new studies, three remaining questions.心房颤动与中风。三项新研究，三个遗留问题。
Arch Intern Med. 1994 Jul 11;154(13):1443-8.
9
Status of antithrombotic therapy for patients with atrial fibrillation in university hospitals.大学医院心房颤动患者的抗栓治疗现状
Arch Intern Med. 1996 Nov 11;156(20):2311-6.
10
A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO).华法林与阿司匹林用于预防老年房颤患者中风的随机对照试验（WASPO）。
Age Ageing. 2007 Mar;36(2):151-6. doi: 10.1093/ageing/afl129. Epub 2006 Dec 15.
本文引用的文献
1
Bleeding complications in oral anticoagulant therapy. An analysis of risk factors.口服抗凝治疗中的出血并发症。危险因素分析。
Arch Intern Med. 1993 Jul 12;153(13):1557-62. doi: 10.1001/archinte.153.13.1557.
2
Risk factors for intracranial hemorrhage in outpatients taking warfarin.服用华法林的门诊患者颅内出血的危险因素。
Ann Intern Med. 1994 Jun 1;120(11):897-902. doi: 10.7326/0003-4819-120-11-199406010-00001.
3
Atrial fibrillation and stroke. Revisiting the dilemmas.
Stroke. 1994 Jul;25(7):1337-41. doi: 10.1161/01.str.25.7.1337.
4
Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications.心房颤动患者的患病率、年龄分布及性别。分析与启示。
Arch Intern Med. 1995 Mar 13;155(5):469-73.
5
Anticoagulation and atrial fibrillation. Putting the results of clinical trials into practice.抗凝与心房颤动。将临床试验结果应用于实践。
West J Med. 1995 Aug;163(2):145-52.
6
Epidemiologic features of chronic atrial fibrillation: the Framingham study.慢性心房颤动的流行病学特征：弗雷明汉姆研究
N Engl J Med. 1982 Apr 29;306(17):1018-22. doi: 10.1056/NEJM198204293061703.
7
The risk of intracerebral hemorrhage during oral anticoagulant treatment: a population study.口服抗凝治疗期间脑出血的风险：一项人群研究。
Ann Neurol. 1984 Nov;16(5):553-8. doi: 10.1002/ana.410160505.
8
The natural history of lone atrial fibrillation. A population-based study over three decades.孤立性心房颤动的自然病史。一项基于人群的三十年研究。
N Engl J Med. 1987 Sep 10;317(11):669-74. doi: 10.1056/NEJM198709103171104.
9
Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study.华法林与阿司匹林预防慢性心房颤动血栓栓塞并发症的安慰剂对照随机试验。哥本哈根AFASAK研究。
Lancet. 1989 Jan 28;1(8631):175-9. doi: 10.1016/s0140-6736(89)91200-2.
10
Canadian Atrial Fibrillation Anticoagulation (CAFA) Study.加拿大房颤抗凝（CAFA）研究
J Am Coll Cardiol. 1991 Aug;18(2):349-55. doi: 10.1016/0735-1097(91)90585-w.
Zotero 插件